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ABSTRACT 
Background and Objectives: Left ventricular hypertrophy (LVH) is a major cardiovascular complication and an 
important predictor of mortality in patients with end stage renal disease. Some studies have shown that the serum 
aldosterone levels are correlated with LVH in non-diabetic patients undergoing hemodialysis. The objective of this 
study was to elucidate the relationships between serum biomarkers, including aldosterone, and echocardiographic 
findings, such as LVH, in patients on peritoneal dialysis. Subjects and Methods: Thirty patients on continuous 
ambulatory peritoneal dialysis (CAPD) for >12 months at Soonchunhyang University Cheonan Hospital were 
included. Transthoracic echocardiography was performed and the left ventricular mass index (LVMI) was cal-
culated using the Devereux formula. Serum biomarkers {N-terminal pro B-type natriuretic peptide (NT-proBNP), 
troponin T, C-reactive protein, renin, and aldosterone} were measured. Results: Sixteen of 30 patients had LVH 
on the basis of the LVMI. The mean serum aldosterone level was 62.53±60.73 pg/mL (range, 5.03-250.68 pg/mL). 
LVH, on the basis of the LVMI, was not correlated with the serum aldosterone level. The serum aldosterone levels 
were not associated with echocardiographic findings, even with co-existing diabetes mellitus. The LVMI had a neg-
ative correlation with the hemoglobin (r=-0.405, p=0.029) and hematocrit (r=-0.374, p=0.042), and a positive 
correlation with NT-proBNP (r=0.560, p=0.002). The other biomarkers (renin, aldosterone, troponin T, and C-
reactive protein) were not correlated with the LVMI. The LVMI was correlated with the left atrium volume index 
(r=0.675, p<0.001). Conclusion: NT-proBNP is a good marker to predict LVH in patients undergoing CAPD. The 
serum aldosterone level is not correlated with LVMI, even with co-existing diabetes mellitus. (Korean Circ J 2009; 
39:488-493) 
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Introduction 
 
Left ventricular hypertrophy (LVH) is a major cardio-
vascular complication and an important predictor of mor-
tality in patients with end stage renal disease (ESRD).
1)2) 
Wang et al.
3) reported that patients undergoing per-
itoneal dialysis had decreased residual kidney function 
and cardiac hypertrophy that combined to adversely in-
crease the overall mortality and risk of cardiovascular 
death.
3)  
Although echocardiography provides an assessment 
of LVH and is an important tool used for the evaluation 
of patients on dialysis, measurement of serum biomar-
kers that reflect myocyte injury is relatively simple, non-
invasive, and may allow better characterization of the 
nature of cardiac disease when present. Cardiac tropo-
nin T (TnT) and N-terminal pro B-type natriuretic pep-
tide (NT-proBNP) have been evaluated as putative prog-
nostic markers of cardiovascular disease in patients with 
ESRD.
4-6) TnT and NT-proBNP have been reported to 
be correlated with LVH in patients on dialysis.
7)8) High 
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sensitivity C-reactive protein (hsCRP), the prototype mar-
ker of inflammation, is highly associated with cardio-
vascular disease in patients with ESRD, and has been re-
ported to be associated with LVH in patients on con-
tinuous ambulatory peritoneal dialysis (CAPD).
2)  
Serum aldosterone levels have been associated with 
various pathologic patterns of the left ventricle in pa-
tients with essential hypertension. In patients with pri-
mary hyperaldosteronism, the early onset of LVH and 
its reversal after treatment is well-known.
9)10) The pri-
mary role of aldosterone in circulatory homeostasis and 
salt/water balance is thought to be mediated by the epi-
thelial mineralcorticoid receptor. In addition, aldoste-
rone binds to myocardial mineralocortical receptors and 
enhances extracellular matrix and collagen deposition 
in the heart. Aldosterone antagonists have been used 
in congestive heart failure patients with normal renal 
function. Some cases have been reported in which the 
use of spironolactone improves cardiac function with-
out hyperkalemia in peritoneal dialysis patients. Recent-
ly, two studies have shown that the left ventricular mass 
index (LVMI) and serum aldosterone levels are correlat-
ed among non-diabetic patients undergoing hemodi-
alysis, and the plasma aldosterone level is independent 
of blood pressure.
11)12) 
However, there have been few studies demonstrating a 
correlation between the LVMI and plasma aldosterone in 
CAPD patients. We hypothesized that aldosterone could 
be a useful serum biomarker in predicting LVMI. Because 
there is a need to determine the best biomarker for pre-
dicting LVH, we investigated the relationship between 
serum biomarkers (TnT, NT-proBNP, CRP, renin, and 
aldosterone) and LVH in patients on peritoneal dialysis. 
 
Subjects and Methods 
 
Patients 
Thirty patients were eligible for the study. The inclu-
sion criteria were continuous peritoneal dialysis treat-
ment for ≥12 months, and no underlying malignan-
cy, chronic liver disease, systemic lupus erythematosus, 
chronic rheumatic heart disease, or congenital heart dis-
ease. All patients had stable body weight and volume 
status. On physical examination, pretibial pitting edema 
was not observed and there was no pleural effusion on 
chest radiography. The heights and weights of all sub-
jects were recorded. The body mass index (BMI) was 
calculated as the weight (kg)/height (m
2). 
The blood pressure and body weight were measured 
before instillation of the dialysate in the peritoneal equi-
librium test (PET). The Investigational Review Board 
of the Cheonan Hospital at Soonchunhyang University 
approved this study. Informed consent was obtained 
from all patients who participated in the study. 
 
Biochemical determinations 
Blood samples were collected at baseline before PET 
with patients in the supine position. The plasma was se-
parated after centrifugation at 2,000 g for 15 minutes; 
the supernatant was stored at -70℃ until used. Routine 
blood chemistry was performed using standard tech-
niques (76600-020; Hitachi, Japan). Commercially avail-
able radioimmunoassay kits were used to measure plas-
ma concentrations of renin (Renin Riabead; Dainabot, 
Tokyo, Japan), aldosterone (Immunotech SA, France), 
and intact parathyroid hormone (PTH) (iPTH, PTH-
120 MIN IRMA; BioSource Europe SA, Belgium). The 
hsCRP was measured by a latex high sensitivity assay. 
The TnT was measured by an electrochemiluminescence 
assay (Roche modular analyzer; Roche Diagnostic GmbH, 
Mannheim, Germany). 
 
Echocardiographic measurements 
Two-dimensional echocardiography was performed 
using a Vivid T-dimension (GE, VingMed, Horten, Nor-
way) with a 3.5 MHz probe in subjects lying in the left 
decubitus position by a single experienced (10 year) 
echocardiographer blinded to all clinical details about 
the patients. All findings were confirmed by the car-
diologist blinded to all of the patients’ clinical details. 
Left ventricle (LV) mass was normalized for height
2.7 
and expressed as the LVMI. The LV mass was obtained 
by the LV short-axis dimension and a simple geometric 
cube formula. According to Devereux et al.,
13) the fol-
lowing equation provides a reasonable determination of 
LV mass in grams: 1.04 {(LVID+PWT+IVST)
3-LVID
3}
×0.8+0.6, where left ventricular internal diameter at 
end-diastole (LVID) represents the internal dimension 
at diastole, posterior wall thickness (PWT) represents 
the PWT, interventricular septal thickness (IVST) re-
presents the interventricular septal thickness, 1.04 is 
the specific gravity of the myocardium, and 0.8 is the 
correction factor. The height-based indexing of the left 
ventricular mass (LVM) was specifically chosen to mini-
mize the potential distortion by extracellular volume ex-
pansion (body surface area indexing is weightsensitive). 
An LVMI value >47 g/m
2.7 in women and >50 g/m
2.7 
in men was considered an indication of LVH. The re-
lative wall thickness (RWT) was calculated as PWT×
2/LVDd, and a value >0.45 was considered to be in-
creased.
14) Using the criteria established by Koren et al.,
15) 
patients with an increased LVMI and increased RWT 
were considered to have concentric LV hypertrophy, and 
those with a normal RWT were considered to have ec-
centric LV hypertrophy. 
Pulse Doppler echocardiography was used to assess 
LV diastolic function. The peak velocity of the early di-
astolic filling wave (E wave) and atrial filling (A wave) 
were recorded and the E-to-A ratio (E/A) was calculat-
ed. The ventricular filling pressure was estimated by  
 
490·LVH and Biomarkers in CAPD 
 
combining the mitral inflow early diastolic velocity (E) 
and the annulus velocity (E’). The patients were classi-
fied according to the E/E’ ratio at rest. A value >15 was 
considered an indication of diastolic dysfunction. 
To estimate the left atrium (LA) volume, the biplane 
area-length formula was used: 8/3π   {(A1) (A2)/(L)}, 
where A1 and A2 represent the maximal planimetered 
LA area acquired from the apical 4- and 2-chamber views, 
respectively, and L is length.
16) The LA volume index was 
calculated as the LA volume/body surface area. 
 
Statistical analysis 
Data are presented as the mean±SD. A probability 
value of a p<0.05 was considered statistically significant. 
All statistical analyses were performed using Statistical 
Package for Social Science (SPSS) for Windows (version 
12.0; SPSS, Inc., Chicago, IL, USA). Continuous varia-
bles were analyzed using the Student’s t-test, and cate-
gorical variables were analyzed using the chi-square test. 
The Pearson correlation was used to identify the correla-
tion between biomarkers and LVMI.   
 
Results 
 
Patients 
The general characteristics of 30 patients on perito-
neal dialysis are summarized in Table 1. Eighteen pa-
tients were diabetic, while 12 patients were non-diabetic. 
Two of the diabetic patients received oral hypoglycemia 
agents; the other patients received insulin injections. No 
patients were treated with thiazolinedione. Antihyper-
tensive drugs were used in 30 patients (angiotensin re-
ceptor blockers, n=28; calcium channel blockers, n=22; 
beta-blockers, n=14; minoxidil, n=2). The residual 
urine volume in 10 patients was <100 mL. 
 
Correlation of aldosterone and the left ventricular 
mass index 
The echocardiography findings are summarized in 
Table 2. Using the LVMI, 16 of 30 patients had LVH. 
The serum aldosterone and renin levels were not cor-
related with the LVMI regardless of the presence of di-
Table 2. Clinical and echocardiographic parameters 
  All patients  Non-DM  DM 
Interventricular septal thickness (mm)  10.08±2.94 8.90±2.86 10.86±2.80 
Posterior wall thickness (mm)  16.42±9.98 18.84±11.85 14.80±8.48 
LV end diastolic diameter (mm)*  48.72±6.92 99.37±36.44 68.85±17.45 
LVMI (g/m
2.7) 51.87±14.62 50.84±18.71 52.56±11.71 
Relative wall thickness
† 0.44±0.94 0.39±0.88 0.48±0.82 
LV ejection fraction (%)  57.50±8.42 57.12±8.93 57.78±8.31 
LA volume index (mL/m
2) 32.27±12.58 36.16±12.92 29.52±11.96 
E/A ratio
† 0.95±0.34 1.22±0.30 0.73±0.16 
E/E’ 15.66±5.27 13.56±5.91 17.35±4.16 
Renin activity (ng/mL/hr)  11.87±8.81 7.99±6.30 14.45±9.44 
Aldosterone (pg/mL)  62.56±60.73 78.99±76.50 51.61±46.77
NT-ProBNP (pg/mL)  5450.62±8528.97 5105.74±9918.56 5680.54±7765.02
TnT (ng/mL)  0.04±0.05 0.01±0.01 0.06±0.05 
hsCRP (mg/dL)  0.57±0.82 0.28±0.42 0.76±0.96 
All values are the mean±SD. *p=0.02 between non-DM and DM.  †p<0.01 between non-DM and DM. DM: diabetes mellitus, LVMI: left 
ventricular mass index, LV: left ventricle, LA: left atrium, E/A ratio: ratio of early-to-late transmitral flow velocity, E/E’: ratio of mitral in-
flow early diastolic velocity-to-annulus velocity, NT-ProBNP: N-terminal pro B-type natriuretic peptide, TnT: troponin T, hsCRP: High sen-
sitivity C-reactive protein   
Table 1. Demographic characteristics of the patients 
Age (years)  51.9±14.99 (29, 82)
Gender (male : female) 15  : 15 
Duration of peritoneal dialysis (months)  37.77±24.12 
Underlying diseases   
Diabetes 18 
Hypertension  04 
Chronic glomerulonephritis  07 
Renal tuberculosis  01 
Body mass index (kg/m
2) 25.2±5.7 
Systolic blood pressure (mmHg)  126.7±13.8 
Diastolic blood pressure (mmHg)  76.3±11.0 
Albumin (mg/dL)  3.71±0.43 
Blood urea nitrogen (mg/dL)  49.29±17.84 
Creatinine (mg/dL)  9.14±3.64 
Hemoglobin (mg/dL)  10.22±1.03 
Hematocrit 30.60±3.53 
Renin activity (ng/mL/hr)  11.87±8.81 
Aldosterone (pg/mL)  62.56±60.73 
NT-ProBNP (pg/mL)  5450.62±8528.97
TnT (ng/mL)  0.04±0.05 
hsCRP (mg/dL)  0.57±0.82 
NT-ProBNP: N-terminal proB-type natriuretic peptide, TnT: Tro-
ponin T, hsCRP: high sensitivity C-reactive protein 
  
 
Sang-Ho Park, et al.·491 
abetes mellitus (DM) (Fig. 1A); although the plasma al-
dosterone levels were negatively correlated with the sys-
tolic blood pressure (r=-0.524, p=0.003). There was no 
difference in serum aldosterone levels between patients 
with LVH and patients without LVH (70.53±76.32 
versus 55.83±44.39 pg/mL) (Table 3). The serum al-
dosterone levels were not correlated with other biomar-
kers (TnT, NT-proBNP, hsCRP, and renin). The LVMI 
had a positive correlation with NT-proBNP (r=0.560, 
p=0.002) (Fig. 1B). 
 
Comparison of the left ventriclular geometry with 
the biomarkers 
According to the LV geometry, nine patients had ec-
centric LVH (EH), and the other seven patients had con-
centric LVH (CH). When the EH and CH groups with 
LVH were evaluated, they had no significant differences 
associated with the LVMI, renin, aldosterone, or hsCRP. 
However, NT-proBNP was significantly higher in the 
CH group than the EH group (5502.31±4301.20 vs. 
9797.71±7242.50 pg/mL, p=0.039). 
According to the ejection fraction, the LVMI was high-
er in patients with an ejection fraction <55% compared 
to the patients with an ejection fraction >55% (39.34±
13.11 vs. 23.32±5.22, p<0.01).  
 
Comparison of diastolic markers with the other var-
iables 
According to the LA volume index, 16 patients had 
diastolic dysfunction (≥28 mL/m
2). There were no sig-
nificant differences in serum biomarkers between pa-
tients with diastolic dysfunction and those without dia-
stolic dysfunction. The LVMI was significantly higher 
in patients with diastolic dysfunction (LA volume index 
Table 3. Comparison of variables with respect to left ventricular hypertrophy
  Patients without LVH  Patients with LVH  p 
Duration of peritoneal dialysis (months)  39.07±21.97 36.63±26.52  <0.787
Age (years)  49.50±15.4 54.00±14.79  <0.422
Systolic blood pressure (mmHg)  124.7±14.4 128.4±13.5  <0.479
Diastolic blood pressure (mmHg)  75.8±9.5 76.8±12.5  <0.815
Hemogloblin (mg/dL)  10.70±0.97 9.84±0.93  <0.023
Hematocrit 32.31±3.41 29.10±2.98  <0.010
Renin activity (ng/mL/hr)  12.28±9.57 11.50±8.39  <0.814
Aldosterone (pg/mL)  70.54±76.33 55.58±44.39  <0.511
NT-ProBNP (pg/mL)  3243.84±6636.78 7381.55±44.39  <0.190
TnT (ng/mL)  0.038±0.039 0.042±0.580  <0.829
hsCRP (mg/dL)  0.50±0.88 0.63±0.78  <0.672
LVMI (g/m
2.7) 40.32±5.16 61.98±12.51  <0.001
RWT 0.45±0.12 0.44±0.07  <0.840
LVEF (%)  61.94±4.83 53.36±9.05  <0.004
E/E’ 13.05±3.36 18.48±5.60  <0.005
E/A 0.98±0.37 13.05±3.36  <0.623
LA volume index (mL/m
2) 24.81±6.55 39.23±13.02  <0.001
LVMI: left ventricular mass index, LA: left atrium, E/E’: ratio of mitral inflow early diastolic velocity-to-annulus velocity, NT-ProBNP: N-ter-
minal pro B-type natriuretic peptide, TnT: troponin T, hsCRP: High sensitivity C-reactive protein, LVH: left ventricular hypertrophy, RWT: rel-
ative wall thickness, LVEF: left ventricular ejection fraction, E/A: ratio of the peak velocity of the early diastolic filling wave of atrial filling wave
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Fig. 1. Relationship of LVMI and aldosterone or NT-proBNP. A: there was no relationship between LVMI and aldosterone. B: there was
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≥28 mL/m
2) than in those without diastolic dysfunc-
tion (LA volume index <28 mL/m
2; 42.48±8.63 vs. 
59.12±14.79 g/m
2.7, p=0.001). The LA volume index 
was correlated with the LVMI (r=0.675, p<0.001). Ac-
cording to the E/E’, the renin activity was higher in pa-
tients with diastolic dysfunction (E/E’  ≥15) compared 
to the other patients (10.76±2.88 vs. 4.67±1.30, p= 
0.04); however, NT-proBNP was not different between 
the two groups. The LVMI was significantly higher in 
patients with diastolic dysfunction (E/E’ ≥15) than in 
those without diastolic dysfunction (E/E’ <15; 44.28±
10.11 vs. 50.03±16.66 g/m
2.7, p=0.025). The E/E’ was 
correlated with the LVMI (r=0.640, p<0.001). The E/A 
ratio was not correlated with the LVMI.   
 
Discussion 
 
Serum aldosterone has recently been reported to play 
a significant role in cardiac hypertrophy independent of 
its effect on blood pressure.
17) There are no differences 
in the mean value of plasma aldosterone between nor-
mal subjects and hypertensive patients.
18) Aldosterone 
antagonists have been shown to be effective in patients 
with heart failure and after an acute myocardial infarc-
tion (MI) with adequate renal function. The use of al-
dosterone antagonists is generally contraindicated in 
severe renal dysfunction, although some cases have re-
ported that spironolactone could improve cardiac func-
tion in ESRD patients. Once patients have progressed 
to ESRD, aldosterone levels may remain elevated.
19) In 
theory, the elevation of aldosterone might injure cardiac 
muscle in ESRD patients. In a few studies involving he-
modialysis patients, aldosterone was only correlated with 
the LVMI in non-diabetic patients.
11)12) Our study show-
ed that aldosterone was not correlated with the LVMI, 
even with co-existing DM. We reasoned that this differ-
ence could be influenced by dialysis modality and blood 
pressure.
20) In Sato’s study,
12) a decrease in aldosterone 
was observed after hemodialysis, possibly due to volume 
status or clearance by dialysis; however, the volume sta-
tus is steady in stable peritoneal dialysis. The control of 
blood pressure might influence the aldosterone level 
in ESRD. We previously reported that aldosterone con-
centrations before and after hemodialysis were signifi-
cantly lower in patients with uncontrolled blood pres-
sure than in patients with well-controlled blood pressure. 
In the current study, aldosterone was negatively corre-
lated with systolic blood pressure, which is inconsistent 
with Sato’s study.
12) Thus, aldosterone levels in CAPD 
patients might be more influenced by blood pressure 
than LVMI. In a study of 115 hypertensive patients, Ma-
lmqvist et al.
21) reported plasma renin activity (PRA) 
and aldosterone, two markers of the angiotensin-al-
dosterone system (RAAS), were related to LV mass and 
RWT, whereas in a study of Korean 275 essential hy-
pertensive patients, PRA was not related to LVMI.
22) In 
our study, PRA was not related to LVMI. RAAS could 
be influenced by antihypertensive drugs, but in our 
study, the PRA and aldosterone level were not different 
according to use of antihypertensive drugs. The results 
of our study showed that NT-proBNP, among the bio-
markers investigated, was correlated with the LVMI. This 
finding is consistent with previous reports. In our study, 
troponin T was not correlated with the LVMI and NT-
proBNP. NT-proBNP was a superior marker for the pre-
diction of the LVMI compared to TnT in patients re-
ceiving peritoneal dialysis. Concentric LVH has been 
shown to be associated with more marked vascular al-
terations in ESRD
23)24) and a poorer patient outcome.
15)25) 
Our results showed that NT-proBNP and residual renal 
function might be associated with LV geometry. These 
results suggest that a worsening of residual renal func-
tion might effect the concentric left ventricular remodel-
ing and that NT-proBNP might be a good marker for 
concentric left ventricular remodeling. 
The E/A, E/E’, and LA volume are known as mark-
ers for diastolic dysfunction. The LVMI has been shown 
to be associated with diastolic dysfunction.
26) The LA 
volume index has been recognized as a marker of the 
chronicity of LV diastolic dysfunction.
27) In Cho’s study,
28) 
the left atrial volume index and the E/E’ demonstrated 
a progressive worsening of the left ventricular diastolic 
function from patients with normal geometry to the pa-
tients with concentric remodeling, and then to the pa-
tients with eccentric and concentric hypertrophy in a 
patient population with hypertension, but without sys-
tolic dysfunction. In the present study, the LA volume 
index and E/E’ showed a very good correlation with the 
LVMI; the LVMI was significantly higher with diastolic 
dysfunction (LV volume index ≥28 mL/m
2 or E/E’ 
≥15) than without diastolic dysfunction (LV volume 
index <28 mL/m
2 or E/E’ <15). Aldosterone was not 
correlated with diastolic dysfunction marker. 
In conclusion, the results of this study suggest that 
NT-proBNP is a good marker to predict LVH in CAPD 
patients and aldosterone was not correlated with LVMI, 
even with co-existing DM in stable CAPD patients.   
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